SEC Form 4 · accession 0001104659-18-051502
NOVELION THERAPEUTICS INC. · NVLN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Donald K Stern
Director
Period of report
Aug 9, 2018
Accepted (ET)
Aug 13, 2018 · 4:30 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000827809
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1,F2 | $3.33 | Aug 9, 2018 | A | 10,000 | A | — | Aug 9, 2028 | Common Shares | 10,000 | 10,000 | D |
Explanation of responses
- F1Each option has an exercise price equal to the closing price of a common share of the Issuer on the Nasdaq Global Select Market on the grant date.
- F2The option shall vest in twelve equal monthly installments, beginning one month after the grant date.